NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 58 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 77 → 74 locations
- Notable Eligibility criteria expanded, about 14 words
- Study sites: 78 to 77
- Secondary endpoints: details revised at 1 of 11 entries
- Minor Trial sites reduced: 82 → 78 locationsv56
- Minor Study sites: 83 to 82v55
- Minor Study sites: 84 to 83v54
Show 3 earlier versionsHide 3 earlier versions
- Minor Site details revised at 1 of 84 sitesv53
- Minor Site details revised at 2 of 84 sitesv52
- Minor Study sites: 83 to 84v51
- Minor Trial sites expanded: 80 → 83 locationsv50
- Minor Trial sites reduced: 83 → 80 locationsv49
- Minor Study sites revised (83)v48
- Minor Study sites: 84 to 83v47
- Minor Site details revised at 3 of 84 sitesv46
- Minor Site details revised at 1 of 84 sitesv45
- Minor Study sites: 85 to 84v44
- Minor Study sites: 86 to 85v43
- Minor Study sites: 88 to 86v42
- Notable Lead sponsor: BeiGene to BeOne Medicines
- Study sites: 93 to 88
- Minor Study sites: 94 to 93v40
- Minor Site details revised at 2 of 94 sitesv39
- Minor Study sites: 89 to 94v38
- Minor Study sites: 88 to 89v37
- Minor Site details revised at 2 of 88 sitesv36
Notable Eligibility criteria expanded, about 48 wordsv35 Show 4 more changesShow less
- Primary endpoints revised (5)
- Enrollment target: 167 to 246
- Secondary endpoints revised (11)
- Site details revised at 5 of 88 sites
- Minor Study sites: 89 to 88v34
- Minor Study sites: 88 to 89v33
- Minor Interventions: BGB-11417 (Drug), Carfilzomib (Drug), Dexamethasone (Drug) to Carfilzomib (Drug), Daratumumab (Drug), Dexamethasone (Drug), Pomalidomide (Drug), Sonrotoclax (Drug)v32
- Minor Site details revised at 1 of 88 sitesv31
- Minor Study sites: 32 to 88v30
- Minor Study sites: 77 to 32v29
- Minor Study sites: 70 to 77v28
- Minor Study sites: 71 to 70v27
- Minor Study sites: 69 to 71v26
- Minor Study sites: 64 to 69v25
- Minor Study sites revised (64)v24
- Minor Study sites: 61 to 64v23
- Minor Study sites: 56 to 61v22
- Minor Study sites: 49 to 56v21
- Minor Study sites: 42 to 49v20
- Minor Study sites: 27 to 42v19
- Minor Study sites revised (27)v18
- Minor Study sites: 24 to 27v17
- Minor Study sites: 23 to 24v16
- Minor Study sites: 74 to 23v15
- Minor Study sites: 24 to 74v13
- Notable Primary and study completion dates pushed to Nov 2026
- Study sites revised (24)
- Minor Study sites: 22 to 24v11
- Minor Study sites: 21 to 22v10
- Minor Study sites: 6 to 21v9
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.
There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab
Drugs: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Sites
74 sites in 13 countries
China 21, United States 15, Brazil 7, Australia 6, Italy 5, South Korea 5, Germany 4, Canada 3, United Kingdom 3, Greece 2, France 1, Singapore 1, Spain 1